Protein antigen design and production platform supporting therapeutic antibody and vaccine discovery.
Macrotope
Macrotope: Your partner in therapeutic antibody and vaccine discovery with expert protein antigen design.
Founded
2015Macrotope: Your partner in therapeutic antibody and vaccine discovery with expert protein antigen design.
Founded with a mission to revolutionize immunology, Macrotope specializes in protein antigen design and production to support therapeutic antibody and vaccine discovery. The company leverages its extensive IP portfolio and decades of experience in antigen production, protein folding, and biochemistry to offer cutting-edge solutions. Macrotope's core product, the MacroAntigen™ Platform, is designed to enhance the immune response, making it a crucial partner for organizations focused on developing innovative vaccines and antibodies.
Macrotope's team comprises leading experts in immunology and biochemistry, contributing to its reputation as a pioneer in antigen-centric approaches. The company has garnered attention from notable investors in the biotech sector, further validating its impact and potential. Key achievements include the successful integration of its MacroAntigen Vaccine (MAV™) technology into various therapeutic pipelines, significantly advancing the field of antibody discovery. Overall, Macrotope has made substantial contributions to immunological research and therapeutic development, positioning itself as a vital player in the biotech industry.
Companies similar to Macrotope include Macromoltek, Proteinea, ImmPro and Unnatural Products.
Macrotope was founded in 2015.
Macrotope's headquarters is located in Princeton, NJ, US.
Macrotope's most recent funding round was for $300k (USD) in August 2023.
As of Aug 18, 2023, Macrotope has disclosed funding of $500k (USD). Undisclosed round amounts are excluded.
Macrotope has 5 employees as of Feb 5, 2024.
Unnatural Products